Meet our executive team

Fredrik Palm

Chief Executive Officer
Palm transitioned into the role of CEO of Inify Laboratories in early 2022, after having been CEO of ContextVision 2019–2022, and VP of Medical Imaging before that. Palm has over 20 years of experience in international life science business. After many years at Waters Corporation, he moved on to several management positions in medical device companies, focusing on domestic and international expansion. His experience covers commercial operations and business development. Palm has supplemented his engineering background with studies in business management and strategic marketing.

As of June 20, 2022 Fredrik Palm holds a total of 53,070 shares in the Company.

Ann-Charlotte Linderoth

Chief Financial Officer
Linderoth joined Inify Laboratories as Chief Financial Officer (CFO) in 2022 after holding the corresponding position at ContextVision since 2015. Linderoth has over 25 years of experience from various financial positions, mostly from companies within the field of medical devices. She holds a Bachelor of Science in Business Administration and Economics from the University of Stockholm

As of June 20, 2022 Ann-Charlotte Linderoth holds a total of 50,740 shares in the Company.

Magnus Aurell

Commercial Director
Aurell joined ContextVision in May 2020 as VP of Digital Pathology and continued into Inify Laboratories as Commercial Director. Aurell has over 25 years of experience from the MedTech and pharma industry. His main focus has been on international commercialization and business development, through both product development and expansions into new geographical markets. Previously, Aurell was Business Unit Manager at AMRA Medical. Prior to that, he was CEO of EXINI Diagnostics, where he was responsible for the sale and integration of the company into Progenics Pharmaceutical, who acquired EXINI for their unique imaging biomarker within prostate cancer. Magnus holds a Master of Science degree in Biophysics from Uppsala University.

As of June 20, 2022 Magnus Aurell holds a total of 5,000 shares in the Company.

Emelie Edvigsson

Laboratory Manager
Edvigsson joined Inify Laboratories in January 2022 as Laboratory Manager. She has over 15 years of experience in lab operations and management, working as a Biomedical Scientist in both public healthcare and in the private sector. Before her current position, she served as Synlab Medilabs’s Department Manager for Clinical Histopathology and Cytology. Her main focus has been streamlining lab workflows, quality improvement and analysis development. Edvigsson holds a Biomedical Scientist degree from Umeå University.

As of June 20, 2022 Emelie Edvigsson holds a total of 0 shares in the Company.

Arto Järvinen

Chief Technical Officer
Järvinen joined Inify Laboratories in 2022, after about 10 years within R&D in ContextVision, most recently as CTO. He started his career at ContextVision in 1984, shortly after it was founded, having just majored in image processing at the Linköping and Stanford universities. Three years later, he left to work for the Swedish Attaché of Science and Technology in San Francisco. Since then, his career has included various management and consulting positions, such as management consultant at a global management consultancy, chief quality officer for a global PACS company and managing director for a medical device company. Järvinen’s expertise includes machine learning, image processing, system development, operational excellence, medical device regulations and management of high-tech companies in general.

As of June 20, 2022 Arto Järvinen holds a total of 11,500 shares in the Company.

Johanna Karling

Chief Quality and Regulatory Affairs Officer
Karling is responsible for Quality Assurance, Accreditation and Regulatory Affairs at Inify Laboratories. She has more than 30 years of experience within the pharmaceutical and medical device industries, specializing within the field of QA and regulatory affairs. She has been QA and Regulatory Affairs Director at the medical device companies Aerocrine AB and Bactiguard AB, and most recently at ContextVision AB for four years. Karling’s experience includes building up and optimizing Quality Management Systems, establishing regulatory strategies, handling product registrations, and performing Quality Management System audits. She holds a MSc degree in Biochemical Engineering from the Royal Institute of Technology in Stockholm.

As of June 20, 2022 Johanna Karling holds a total of 6,400 shares in the Company.